-
Frontiers in Cellular and Infection... 2022Visceral leishmaniasis (VL) and post kala-azar dermal leishmaniasis (PKDL) affect most of the poor populations worldwide. The current treatment modalities include...
Visceral leishmaniasis (VL) and post kala-azar dermal leishmaniasis (PKDL) affect most of the poor populations worldwide. The current treatment modalities include liposomal formulation or deoxycholate salt of amphotericin B, which has been associated with various complications and severe side effects. Encouraged from the recent marked antimalarial effects from plant-derived glycosides, in this study, we have exploited a green chemistry-based approach to chemically synthesize a library of diverse glycoside derivatives (Gly1-12) and evaluated their inhibitory efficacy against the AG83 strain of . Among the synthesized glycosides, the inhibitory activity of Glycoside-2 (Gly2) (1.13 µM IC50 value) on promastigote demonstrated maximum cytotoxicity with ~94% promastigote death as compared to amphotericin B that was taken as a positive control. The antiproliferative effect of Gly2 on promastigote encouraged us to analyze the structure-activity relationship of Gly2 with Gp63, a zinc metalloprotease that majorly localizes at the surface of the promastigote and has a role in its development and multiplication. The result demonstrated the exceptional binding affinity of Gly2 toward the catalytic domain of Gp63. These data were thereafter validated through cellular thermal shift assay in a physiologically relevant cellular environment. Mechanistically, reduced multiplication of promastigotes on treatment with Gly2 induces the destabilization of redox homeostasis in promastigotes by enhancing reactive oxygen species (ROS), coupled with depolarization of the mitochondrial membrane. Additionally, Gly2 displayed strong lethal effects on infectivity and multiplication of amastigote inside the macrophage in the amastigote-macrophage infection model as compared to amphotericin B treatment. Gp63 is also known to bestow protection against complement-mediated lysis of parasites. Interestingly, Gly2 treatment enhances the complement-mediated lysis of promastigotes in serum physiological conditions. In addition, Gly2 was found to be equally effective against the clinical promastigote forms of PKDL strain (IC50 value of 1.97 µM); hence, it could target both VL and PKDL simultaneously. Taken together, this study reports the serendipitous discovery of Gly2 with potent antileishmanial activity and proves to be a novel chemotherapeutic prototype against VL and PKDL.
Topics: Amphotericin B; Antiprotozoal Agents; Glycosides; Humans; Leishmania donovani; Leishmaniasis, Visceral; Metalloproteases
PubMed: 35601095
DOI: 10.3389/fcimb.2022.803048 -
PLoS Neglected Tropical Diseases Feb 2024Visceral leishmaniasis (VL) resolution depends on a wide range of factors, including the instauration of an effective treatment coupled to a functional host immune...
BACKGROUND
Visceral leishmaniasis (VL) resolution depends on a wide range of factors, including the instauration of an effective treatment coupled to a functional host immune system. Patients with a depressed immune system, like the ones receiving methotrexate (MTX), are at higher risk of developing VL and refusing antileishmanial drugs. Moreover, the alarmingly growing levels of antimicrobial resistance, especially in endemic areas, contribute to the increasing the burden of this complex zoonotic disease.
PRINCIPAL FINDINGS
To understand the potential links between immunosuppressants and antileishmanial drugs, we have studied the interaction of antimony (Sb) and MTX in a Leishmania infantum reference strain (LiWT) and in two L. infantum clinical strains (LiFS-A and LiFS-B) naturally circulating in non-treated VL dogs in Spain. The LiFS-A strain was isolated before Sb treatment in a case that responded positively to the treatment, while the LiFS-B strain was recovered from a dog before Sb treatment, with the dog later relapsing after the treatment. Our results show that, exposure to Sb or MTX leads to an increase in the production of reactive oxygen species (ROS) in LiWT which correlates with a sensitive phenotype against both drugs in promastigotes and intracellular amastigotes. LiFS-A was sensitive against Sb but resistant against MTX, displaying high levels of protection against ROS when exposed to MTX. LiFS-B was resistant to both drugs. Evaluation of the melting proteomes of the two LiFS, in the presence and absence of Sb and MTX, showed a differential enrichment of direct and indirect targets for both drugs, including common and unique pathways.
CONCLUSION
Our results show the potential selection of Sb-MTX cross-resistant parasites in the field, pointing to the possibility to undermine antileishmanial treatment of those patients being treated with immunosuppressant drugs in Leishmania endemic areas.
Topics: Humans; Animals; Dogs; Leishmania infantum; Methotrexate; Antimony; Reactive Oxygen Species; Antiprotozoal Agents; Leishmaniasis, Visceral; Drug Resistance
PubMed: 38422164
DOI: 10.1371/journal.pntd.0012015 -
Journal of Animal Physiology and Animal... Jul 2020Four Small-tail Han male hogget sheep, fitted with rumen cannula and fed the same basal diet were used to study the impacts of docusate (DOC) and fauna-free on the...
Four Small-tail Han male hogget sheep, fitted with rumen cannula and fed the same basal diet were used to study the impacts of docusate (DOC) and fauna-free on the voluntary feed intake (VFI), and ruminal protozoal, bacterial and fungal counts and the digestive enzyme activities. By a 4 × 4 Latin square design, sheep were given no DOC (the control), 2 doses of DOC: 1.2 and 3.0 g/kg diet or oral dose of 6.0 g/d DOC for three days (fauna-free treatment) in each period of 18 days, the last three days of which were for sampling the rumen fluid. Compared with the control, 1.2 g/kg of DOC supplementation significantly resulted in increases of 18.0% VFI and 44% bacterial count, and no significant change in the fungal number. Supplementing DOC reduced protozoal number in a dose-dependent manner. The fibre degradation enzyme activity in rumen fluid increased by 17.7% with a concomitant 10% increase in volatile fatty acids (VFA); the protease activity was reduced by 23% with a corresponding reduction in rumen ammonia by 42%. In contrast, supplementing 3.0 g/kg of DOC has adverse effects on those measures compared with 1.2 g/kg of DOC. Defaunation was accompanied with substantial increases in the bacterial and fungal counts, but had no significant influences on VFI and the enzyme activity for starch, protein and pectin digestion, and small changes in fibre digestion enzymes and the total VFA compared with the control. A high correlation (r = 0.82) was noted between VFI and the total activity of fibre digestion enzymes and VFA. It was proposed that fibre digestion rate in the rumen is a primary factor for determining VFI in sheep, and dietary supplementation of 1.2 g/kg of DOC could partially result in enhanced activity of fibre digestive enzyme in the rumen and increase VFI.
Topics: Ammonia; Animal Feed; Animals; Antiprotozoal Agents; Diet; Digestion; Dioctyl Sulfosuccinic Acid; Enzymes; Fatty Acids, Volatile; Gastrointestinal Contents; Hydrogen-Ion Concentration; Male; Rumen; Sheep
PubMed: 32383244
DOI: 10.1111/jpn.13382 -
Parasitology Apr 2022Cutaneous leishmaniasis (CL) is a spectrum of clinical manifestations characterized by severe skin ulcerations that leads to social stigma. There are limited treatment...
Cutaneous leishmaniasis (CL) is a spectrum of clinical manifestations characterized by severe skin ulcerations that leads to social stigma. There are limited treatment options for CL, and the available drugs are becoming less efficacious due to drug resistance. More efficacious and safer antileishmanial drugs are needed. In this study, the biological effect of seven synthetically accessible nitroaromatic compounds was evaluated in vitro against amastigotes of Leishmania amazonensis, followed by in vivo evaluation using mouse models of CL. Two compounds (6 and 7) were active against amastigotes in vitro [half-maximal effective concentration (EC50): 4.57 ± 0.08 and 9.19 ± 0.68 μm, respectively], with selectivity indexes >50, and the other compounds were not selective. In vivo, compounds 6 and 7 (10 mg kg−1, twice a day for 14 days) failed to reduce skin lesion sizes and parasite loads determined by light microscopy of lesion imprints and quantitative polymerase chain reaction. Nevertheless, the in vitro leishmanicidal efficacy sustained their use as templates for nitroimidazole-based antileishmanial drug discovery programmes focusing on analogues with more suitable properties.
Topics: Animals; Antiprotozoal Agents; Leishmania mexicana; Leishmaniasis, Cutaneous; Mice; Mice, Inbred BALB C; Nitro Compounds
PubMed: 35109958
DOI: 10.1017/S0031182021002079 -
Turkiye Parazitolojii Dergisi May 2022Leishmaniasis is the second deadliest parasitic disease in the World Health Organisation's list of neglected diseases, following malaria. Cutaneous leishmaniasis (CL) is...
OBJECTIVE
Leishmaniasis is the second deadliest parasitic disease in the World Health Organisation's list of neglected diseases, following malaria. Cutaneous leishmaniasis (CL) is the most common form of the disease and it is one of the few communicable diseases with increasing incidence rates owing to factors like armed conflicts and climate change. CL can be divided into two major groups: Acute CL (ACL) and chronic CL (CCL). The aim of this study was to compare the efficacy of miltefosine and pentavalent antimony compounds in the CCL patient samples.
METHODS
Five isolates previously isolated from 5 CCL patients were included in this study. Genotyping is performed using internal transcribed spacer 1 (ITS 1) gene region real-time PCR. drug efficacy tests were applied to determine their activity against meglumine antimoniate (MA) and miltefosine. Serial dilutions (512, 256, 128, 64, 32, 16, 8 and 4 µg/mL) prepared from MA and miltefosine were prepared in 96-well flat-bottom cell culture plates and incubated at 24 °C for 48 hours. The efficacy of the drug on spp. promastigotes after 24 and 48 hours was evaluated by hemocytometer slide and XTT cell viability test.
RESULTS
All of the samples were genotyped as . Evaluation of 24 and 48 hours showed, 128 µg/mL and 256 µg/mL and 32 µg/mL and 64 µg/mL concentrations of miltefosine and MA were enough to kill all the promastigotes respectively. The results of the hemocytometer slide and XTT were consistent.
CONCLUSION
There are no studies investigating the efficacy of miltefosine with the CCL patient group. To overcome the treatment challenges experienced in this special patient group, more studies are needed. According to our results, it is concluded that miltefosine is efficient for the treatment of CCL and further clinical studies with miltefosine will reveal valuable data.
Topics: Antiprotozoal Agents; Humans; Leishmaniasis, Cutaneous; Meglumine Antimoniate; Phosphorylcholine
PubMed: 35604185
DOI: 10.4274/tpd.galenos.2022.85856 -
Biomedicine & Pharmacotherapy =... Oct 2020Australian tea tree (Melaleuca alternifolia) oil (TTO) and its monoterpene constituents such as terpinen-4-ol (T4O), 1,8-cineole, limonene, p-cymene, and α-terpinene... (Review)
Review
Australian tea tree (Melaleuca alternifolia) oil (TTO) and its monoterpene constituents such as terpinen-4-ol (T4O), 1,8-cineole, limonene, p-cymene, and α-terpinene have been shown to be effective in controlling a wide range of parasitic infections. The anti-parasitic effects of these compounds are mainly due to their anti-histamine and anti-acetylcholinesterase activities as well as their ability to modulate host inflammatory responses. This review attempts to summarize recent advances in the uses of TTO and its 15 major monoterpene constituents in treating parasitic infections in both humans and animals. Activities against parasitic protozoans (Plasmodium falciparum, Leishmania spp., Trypanosoma spp., Acanthamoeba castellanii, Trichomonas vaginalis, Eimeria, and Ichthyophthirius multifiliis), nematodes (Haemonchus contortus and Anisakis simplex), cestode (Echinococcus ortleppi), and monogeneans (Gasterosteus spp. and Dactylogyrus minutus) have been reported, showing good potentials in treating parasitic infections. Further studies are necessary for developing anti-parasite therapies using TTO or its monoterpenes constituents.
Topics: Animals; Anti-Infective Agents, Local; Antiprotozoal Agents; Helminthiasis; Humans; Melaleuca; Monoterpenes; Protozoan Infections; Tea Tree Oil
PubMed: 33503761
DOI: 10.1016/j.biopha.2020.110624 -
Frontiers in Cellular and Infection... 2022Leishmaniasis is one of the major public health concerns in Latin America, Africa, Asia, and Europe. The absence of vaccines for human use and the lack of effective... (Review)
Review
Leishmaniasis is one of the major public health concerns in Latin America, Africa, Asia, and Europe. The absence of vaccines for human use and the lack of effective vector control programs make chemotherapy the main strategy to control all forms of the disease. However, the high toxicity of available drugs, limited choice of therapeutic agents, and occurrence of drug-resistant parasite strains are the main challenges related to chemotherapy. Currently, only a small number of drugs are available for leishmaniasis treatment, including pentavalent antimonials (Sb), amphotericin B and its formulations, miltefosine, paromomycin sulphate, and pentamidine isethionate. In addition to drug toxicity, therapeutic failure of leishmaniasis is a serious concern. The occurrence of drug-resistant parasites is one of the causes of therapeutic failure and is closely related to the diversity of parasites in this genus. Owing to the enormous plasticity of the genome, resistance can occur by altering different metabolic pathways, demonstrating that resistance mechanisms are multifactorial and extremely complex. Genetic variability and genome plasticity cause not only the available drugs to have limitations, but also make the search for new drugs challenging. Here, we examined the biological characteristics of parasites that hinder drug discovery.
Topics: Amphotericin B; Antiprotozoal Agents; Genetic Variation; Humans; Leishmania; Leishmaniasis
PubMed: 35141175
DOI: 10.3389/fcimb.2022.826287 -
International Journal of Pharmaceutics Oct 2020Leishmaniasis is a neglected disease presenting cutaneous, mucosal and visceral forms and affecting an estimated 12 million mostly low-income people. Treatment of...
Leishmaniasis is a neglected disease presenting cutaneous, mucosal and visceral forms and affecting an estimated 12 million mostly low-income people. Treatment of cutaneous leishmaniasis (CL) is recommended to expedite healing, reduce risk of scarring, prevent parasite dissemination to other mucocutaneous (common with New World species) or visceral forms and reduce the chance of relapse, but remains an unmet need. Available treatments are painful, prolonged (>20 days) and require hospitalisation, which increases the cost of therapy. Here we present the development of optimised topical self-nanoemulsifying drug delivery systems (SNEDDS) loaded with buparvaquone (BPQ, a hydroxynapthoquinone from the open Malaria Box) for the treatment of CL from New World species. The administration of topical BPQ-SNEDDS gels for 7 days resulted in a reduction of parasite load of 99.989 ± 0.019% similar to the decrease achieved with intralesionally administered Glucantime® (99.873 ± 0.204%) in a L. amazonensis BALB/c model. In vivo efficacy was supported by ex vivo permeability and in vivo tape stripping studies. BPQ-SNEDDS and their hydrogels demonstrated linear flux across non-infected CD-1 mouse skin ex vivo of 182.4 ± 63.0 μg cm h and 57.6 ± 10.8 μg cm h respectively localising BPQ within the skin in clinically effective concentrations (227.0 ± 45.9 μg and 103.8 ± 33.8 μg) respectively. These levels are therapeutic as BPQ-SNEDDS and their gels showed nanomolar in vitro efficacy against L. amazonensis and L. braziliensis amastigotes with excellent selectivity index toward parasites versus murine macrophages. In vivo tape stripping experiments indicated localisation of BPQ within the stratum corneum and dermis. Histology studies confirmed the reduction of parasitism and indicated healing in animals treated with BPQ-SNEDDS hydrogels. These results highlight the potential clinical capability of nano-enabled BPQ hydrogels towards a non-invasive treatment for CL.
Topics: Animals; Antiprotozoal Agents; Hydrogels; Leishmaniasis, Cutaneous; Mice; Mice, Inbred BALB C; Naphthoquinones
PubMed: 32777535
DOI: 10.1016/j.ijpharm.2020.119734 -
The American Journal of Tropical... Oct 2019
Topics: Amphotericin B; Antiprotozoal Agents; Humans; Leishmaniasis
PubMed: 31482790
DOI: 10.4269/ajtmh.19-0568 -
Experimental Parasitology Nov 2022The main form of control of leishmaniasis is the treatment, however various side effects and poor efficacy are associated with presently available drugs. The...
The main form of control of leishmaniasis is the treatment, however various side effects and poor efficacy are associated with presently available drugs. The investigation of bioactive natural products for new antileishmanial drugs is a valid approach. The present study reports the in vitro efficacy of natural isoflavonoids and terpenes against Leishmania infantum and L. amazonensis and their cytotoxicity against HepG2 cells. L. infantum and L. amazonensis promastigotes were exposed to the terpenes kaurenoic acid, xylopic acid, and (-)-α-bisabolol and to the isoflavonoids (-)-duartin and (3R)-claussequinone for antileishmanial activity and to cytotoxicity to HepG2 cells. The most effective substance against both L. infantum and L. amazonensis species was (3R)-claussequinone (IC = 3.21 μg/mL and 2.47 μg/mL, respectively) that disclosed low cytotoxicity against HepG2 cells (CC = 387.79 μg/mL). The efficacy of (3R)-claussequinone against intracellular amastigotes of L. infantum and the externalization of phosphatidylserine in promastigotes of this isoflavanoid were investigated by infection of Raw 264.7 macrophages and marking with Annexin V-FITC and propidium Iodide for flow cytometry analysis. The results for amastigotes showed that (3R)-claussequinone was able to reduce the rate of infection with IC = 4.61 μg/mL and did not alter the externalization of phosphatidylserine. In conclusion it is presently reported, for the first time, the striking antileishmanial activity of (3R)-claussequinone against L. infantum and L. amazonensis associated to low cytotoxicity. Furthermore, these results suggest that (3R)-claussequinone is a new hit aiming to develop new therapeutic alternatives.
Topics: Mice; Animals; Leishmania infantum; Terpenes; Phosphatidylserines; Propidium; Mice, Inbred BALB C; Antiprotozoal Agents; Biological Products
PubMed: 36152879
DOI: 10.1016/j.exppara.2022.108383